CytomX Therapeutics (CTMX) Assets (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Assets came in at $359.4 million in Q1 2026, up 264.84% YoY from $98.5 million in Q1 2025, and up 137.1% on a QoQ basis from $151.6 million in Q4 2025.
CytomX Therapeutics (CTMX) Assets (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Assets data on file, last reported at $359.4 million in Q1 2026.
- Quarterly Assets rose 264.84% year-over-year to $359.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $359.4 million (up 264.84% YoY) and the FY2025 annual result came in at $151.6 million, up 25.75% from the prior year.
- Assets grew to $359.4 million in Q1 2026, from $151.6 million in the prior quarter.
- In the past five years, Assets ranged from a high of $359.4 million in Q1 2026 to a low of $98.5 million in Q1 2025.
- A 5-year average of $203.4 million and a median of $201.8 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2025 — Assets sank 46.67% — and 2026, when it jumped 264.84%.
- Tracing CTMX's Assets over 5 years: stood at $260.9 million in 2022, then dropped by 22.65% to $201.8 million in 2023, then sank by 40.27% to $120.5 million in 2024, then increased by 25.75% to $151.6 million in 2025, then surged by 137.1% to $359.4 million in 2026.
- The last three Assets figures came in at $359.4 million (Q1 2026), $151.6 million (Q4 2025), and $158.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 381.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 381.23 Mn |
| Mar 31, 2026 | 359.36 Mn |
| Dec 31, 2025 | 151.57 Mn |
| Sep 30, 2025 | 158.25 Mn |
| Jun 30, 2025 | 175.06 Mn |
| Mar 31, 2025 | 98.50 Mn |
| Dec 31, 2024 | 120.53 Mn |
| Sep 30, 2024 | 138.98 Mn |
| Jun 30, 2024 | 159.22 Mn |
| Mar 31, 2024 | 184.69 Mn |
| Dec 31, 2023 | 201.79 Mn |
| Sep 30, 2023 | 221.17 Mn |
| Jun 30, 2023 | 209.19 Mn |
| Mar 31, 2023 | 234.63 Mn |
| Dec 31, 2022 | 260.89 Mn |
| Sep 30, 2022 | 226.49 Mn |
| Jun 30, 2022 | 260.09 Mn |
| Mar 31, 2022 | 296.83 Mn |
| Dec 31, 2021 | 339.41 Mn |
| Sep 30, 2021 | 371.23 Mn |